Who
Jean M. Franchi
Chief Financial Officer
Company insider
Files Form 4 as: Chief Financial Officer, Disc Medicine; Director, Biodesix; Chief Financial Officer, Replimune Group; Chief Financial Officer, Merrimack Pharmaceuticals; Chief Financial Officer, Dimension Therapeutics.
In numbers
- Trades disclosed
- 70
- Buys
- 0
- Sells
- 14
- Bought
- $0
- Sold
- $4.9M
- Companies
- 5
- Companies where not an officer
- 1
- First trade
- 1 Feb 2016
- Last trade
- 14 Apr 2026
- Last filed
- 15 Apr 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 14 Apr 2026filed 15 Apr 2026 | IRON Disc MedicineBiotechnology | SEC FORM 4 Sold | $433K6,257 at $69.24 | filing |
| 14 Apr 2026filed 15 Apr 2026 | IRON Disc MedicineBiotechnology | SEC FORM 4 Sold | $433K6,257 at $69.24 | filing |
| 13 Apr 2026filed 15 Apr 2026 | IRON Disc MedicineBiotechnology | SEC FORM 4 Sold | $28K400 at $69.00 | filing |
| 13 Apr 2026filed 15 Apr 2026 | IRON Disc MedicineBiotechnology | SEC FORM 4 Sold | $28K400 at $69.00 | filing |
| 25 Feb 2026filed 27 Feb 2026 | IRON Disc MedicineBiotechnology | SEC FORM 4 Sold | $24K353 at $69.06 | filing |
| 25 Feb 2026filed 27 Feb 2026 | IRON Disc MedicineBiotechnology | SEC FORM 4 Sold | $24K353 at $69.06 | filing |
| 18 Feb 2026filed 19 Feb 2026 | IRON Disc MedicineBiotechnology | SEC FORM 4 Sold | $221K3,397 at $65.01 | filing |
| 18 Feb 2026filed 19 Feb 2026 | IRON Disc MedicineBiotechnology | SEC FORM 4 Sold | $243K3,684 at $65.89 | filing |
| 18 Feb 2026filed 19 Feb 2026 | IRON Disc MedicineBiotechnology | SEC FORM 4 Sold | $221K3,397 at $65.01 | filing |
| 18 Feb 2026filed 19 Feb 2026 | IRON Disc MedicineBiotechnology | SEC FORM 4 Sold | $243K3,684 at $65.89 | filing |
| 17 Feb 2026filed 19 Feb 2026 | IRON Disc MedicineBiotechnology | SEC FORM 4 Sold | $256K4,075 at $62.86 | filing |
| 17 Feb 2026filed 19 Feb 2026 | IRON Disc MedicineBiotechnology | SEC FORM 4 Sold | $256K4,075 at $62.86 | filing |
| 10 Feb 2026filed 11 Feb 2026 | IRON Disc MedicineBiotechnology | SEC FORM 4 Code A | —19,000 at $0.00 | filing |
| 10 Feb 2026filed 11 Feb 2026 | IRON Disc Medicineoption or derivative · Biotechnology | SEC FORM 4 Code A | —25,500 at $0.00 | filing |
| 10 Feb 2026filed 11 Feb 2026 | IRON Disc Medicineoption or derivative · Biotechnology | SEC FORM 4 Code A | —25,500 at $0.00 | filing |
| 10 Feb 2026filed 11 Feb 2026 | IRON Disc MedicineBiotechnology | SEC FORM 4 Code A | —19,000 at $0.00 | filing |
| 2 Jan 2026filed 6 Jan 2026 | BDSX Biodesixoption or derivative · Diagnostics & Labs | SEC FORM 4 Code A | —8,164 at $0.00 | filing |
| 2 Jan 2026filed 6 Jan 2026 | BDSX Biodesixoption or derivative · Diagnostics & Labs | SEC FORM 4 Code A | —6,354 at $0.00 | filing |
| 2 Jan 2026filed 6 Jan 2026 | BDSX Biodesixoption or derivative · Diagnostics & Labs | SEC FORM 4 Code A | —8,164 at $0.00 | filing |
| 2 Jan 2026filed 6 Jan 2026 | BDSX Biodesixoption or derivative · Diagnostics & Labs | SEC FORM 4 Code A | —6,354 at $0.00 | filing |
News
Disc Medicine Prices $450 Mln Offering Of Shares At $75/shr To Fund Pipeline DevelopmentIRON · finanzen.ch · 21 Oct 2026Disc Medicine Launches $350M Stock Offering Following Positive Phase 3 ResultsIRON · rttnews.com · 20 Oct 2026Disc Medicine Announces Proposed $350 Million Public Offering of Common Stock and Pre-Funded WarrantsIRON · manilatimes.net · 19 Oct 2026
0 headlines in the last 90 days name Jean M. Franchi; 3 articles from the last 14 days about the 1 company they traded most, at most three about any one of them.